為探討抑凋亡基因bcl-2蛋白表達(dá)在乳腺癌中的意義,應(yīng)用免疫組織化學(xué)的方法(SP法),對(duì)125例浸潤(rùn)性乳腺癌患者的石蠟包埋組織切片中bcl-2、雌激素受體(ER)、孕激素受體(PR)及p53基因的表達(dá)產(chǎn)物進(jìn)行檢測(cè)。結(jié)果: bcl-2蛋白在浸潤(rùn)性導(dǎo)管癌中的表達(dá)為63.3%,而在浸潤(rùn)性小葉癌中為88.9%,二者間的差異有顯著性意義(P<0.001); 在浸潤(rùn)性導(dǎo)管癌中,bcl-2蛋白的表達(dá)與原發(fā)癌大小及腫瘤分級(jí)呈負(fù)相關(guān)(P<0.05),與ER、PR的表達(dá)呈正相關(guān)(P<0.001),與p53的表達(dá)呈負(fù)相關(guān)(P<0.001)。但未發(fā)現(xiàn)bcl-2表達(dá)與腋窩淋巴結(jié)轉(zhuǎn)移有統(tǒng)計(jì)學(xué)上的顯著性差異。結(jié)論: 乳腺癌bcl-2蛋白表達(dá)與預(yù)后良好的生物學(xué)指標(biāo)有一致性,與預(yù)后不良的指標(biāo)呈反向表達(dá),提示bcl-2蛋白表達(dá)可作為乳腺癌的生物學(xué)指標(biāo),在乳腺癌的病理及臨床中有一定意義。
引用本文: 林清,高東宸,張長(zhǎng)淮,盧小梅,李衛(wèi)民. 乳腺癌中bcl-2蛋白表達(dá)的意義. 中國(guó)普外基礎(chǔ)與臨床雜志, 1999, 6(5): 263-265. doi: 復(fù)制
1. | Shunzo K, Hirotaka I, Yukashi I, et al. Clinical significance of bcl-2 gene expression in human breast cancer tissue. Breast Cancer Res Treatment, 1997; 42(2)∶173. |
2. | Lee WY, Jin YT, Tzeng CC, et al. Reciprocal expression of bcl-2 and p53 in breast ductal carcinoma. Anticancer Research, 1996; 16(5A)∶3007. |
3. | Julia MWG, John FRR, Ian OE, et al. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer, 1994; 59(5)∶619. |
4. | Hellemans P, Van Dam PA, Weyle J. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer, 1995; 72(2)∶354. |
5. | Gasparini G, Barbareschi M, Doglioni C, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatment in operable nodepositive breast cancer. Clin Cancer Res, 1995; 1(2)∶189. |
- 1. Shunzo K, Hirotaka I, Yukashi I, et al. Clinical significance of bcl-2 gene expression in human breast cancer tissue. Breast Cancer Res Treatment, 1997; 42(2)∶173.
- 2. Lee WY, Jin YT, Tzeng CC, et al. Reciprocal expression of bcl-2 and p53 in breast ductal carcinoma. Anticancer Research, 1996; 16(5A)∶3007.
- 3. Julia MWG, John FRR, Ian OE, et al. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer, 1994; 59(5)∶619.
- 4. Hellemans P, Van Dam PA, Weyle J. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer, 1995; 72(2)∶354.
- 5. Gasparini G, Barbareschi M, Doglioni C, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatment in operable nodepositive breast cancer. Clin Cancer Res, 1995; 1(2)∶189.